Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06616363 · ClinicalTrials.gov registry record

Does a Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Nat hx With Its Numerous Co-morbidities?

A clinical trial of POTS - Postural Orthostatic Tachycardia Syndrome, sponsored by Virginia Commonwealth University.

Recruiting
Registry status
120
Enrollment target
1
Study location

NCT06616363: Recruiting study of POTS - Postural Orthostatic Tachycardia Syndrome, sponsored by Virginia Commonwealth University.

NCT06616363 is a study of POTS - Postural Orthostatic Tachycardia Syndrome that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 120 participants, above the 64-participant average among 5 other POTS - Postural Orthostatic Tachycardia Syndrome trials with a reported enrollment target (88% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06616363, a study of POTS - Postural Orthostatic Tachycardia Syndrome, is actively recruiting participants, sponsored by Virginia Commonwealth University.

RECRUITING
Registry status
120 participants
Enrollment target
1
Study location

Study Summary

Postural tachycardia syndrome (POTS) is a common and disabling disorder among adolescents. No epidemiologic data exist to support the often cited 0.5 to 2% prevalence. Case series suggest 3 to 5 times greater incidence in girls than boys. POTS is defined in children as daily chronic symptoms of orthostatic intolerance and a 40 bpm rise in heart rate in the first 10 minutes of a tilt study in the absence of orthostatic hypotension. POTS often develops after an acute event like an illness, infection, immunization, head trauma, psychological trauma or surgery. Natural history data are absent for POTS, though some outcome studies exist. Orthostatic symptoms improve in the majority and heart rate changes improve in 38% at 1 year. A 2-year follow up showed small improvement in comorbid symptoms of POTS in a 12 subject cohort followed yearly. In a pediatric 5-year outcome follow up questionnaire study, 86% of adolescents with POTS reported resolved, improved, or intermittent, symptoms, with primarily physical rather than mental health complaints.

Primary Outcome

The total score determines the level of functional disability, in which higher numbers represent a higher level of disability. There are 15-items and a score of 0 indicates that there are no complaints present whereas 30 indicates that the patient is extremely disabled. The Functional Disability Inventory (FDI) is one of the most widely used measures of functional impairment among children and adolescents with chronic pain. It is expected that there will be higher threat sensitivity that correla

Interventions

  • BEHAVIORAL Questionnaires to be competed
  • BEHAVIORAL Provide list of medication and lifetime events
  • BEHAVIORAL Use phone App to record new life events
  • DEVICE Will wear an activity monitor
  • OTHER Periodic 24-hour urine sodium check

Study Locations (1)

Virginia

  • Virginia Commonwealth University - Richmond

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-05-29
Est. Completion 2028-07
Virginia Commonwealth University

558 total trials

What NCT06616363 shows while recruiting

NCT06616363 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 64-participant average among 5 other POTS - Postural Orthostatic Tachycardia Syndrome trials with a reported enrollment target (88% higher).

The record links to 1 condition, with POTS - Postural Orthostatic Tachycardia Syndrome appearing as the primary indexed condition, and to 5 interventions - of which Questionnaires to be competed is the first listed.

NCT06616363 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT06616363 about?

NCT06616363 is a clinical study titled "Does a Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Nat hx With Its Numerous Co-morbidities?". Postural tachycardia syndrome (POTS) is a common and disabling disorder among adolescents. No epidemiologic data exist to support the often cited 0.5 to 2% prevalence. Case series suggest 3 to 5 times greater incidence in girls than boys. POTS is defined in children as daily chronic symptoms of orth...

What is the current status of trial NCT06616363?

This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2024-05-29. Estimated completion is 2028-07.

What conditions does trial NCT06616363 study?

This clinical trial studies the following conditions: POTS - Postural Orthostatic Tachycardia Syndrome.

What interventions are being tested in trial NCT06616363?

The interventions under investigation include: Questionnaires to be competed (BEHAVIORAL), Provide list of medication and lifetime events (BEHAVIORAL), Use phone App to record new life events (BEHAVIORAL), Will wear an activity monitor (DEVICE), Periodic 24-hour urine sodium check (OTHER).

Who is sponsoring clinical trial NCT06616363?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06616363 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for POTS - Postural Orthostatic Tachycardia Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06616363, the US trial registry maintained by the National Library of Medicine. NCT06616363 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.